Evaluates ubrogepant's effectiveness in optimizing migraine treatment, indicating promising outcomes for patients.
To evaluate real-world optimization of ubrogepant for the acute treatment of migraine when given to participants also taking atogepant using the migraine Treatment Optimization Questionnaire (mTOQ).
No takes yet. Share an insight, caveat, or question.
Nahas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: